For the last two decades, researchers have placed hopes in a new era in which a
combination of reperfusion and neuroprotection would revolutionize the treatment of stroke …

The immune response to stroke is an exciting target for future stroke therapies. Stroke is a
leading cause of morbidity and mortality worldwide, and clot removal (mechanical or …

Inflammation is currently considered a prime target for the development of new stroke
therapies. In the acute phase of ischemic stroke, microglia are activated and then circulating …

Stroke is a major cause of morbidity and mortality worldwide. Despite the intensive search
for new therapies, hundreds of agents targeting various pathophysiological mechanisms …

Ischemic stroke generates an immune response that contributes to neuronal loss as well as
tissue repair. This is a complex process involving a range of cell types and effector …

Ischemic stroke is the most frequent cause of persistent neurologic disability in modern
Western societies. Albeit it is still not clear whether inflammation is merely an …

The immune response to acute cerebral ischemia is a major factor in stroke pathobiology
and outcome. While the immune response starts locally in occluded and hypoperfused …

Stroke is one of the leading causes of death and disability worldwide. The long‐standing
dogma that stroke is exclusively a vascular disease has been questioned by extensive …

Although several studies have suggested that anti-inflammatory strategies reduce
secondary infarct growth in animal stroke models, clinical studies have not yet demonstrated …

Over the past several decades, there have been substantial advances in our knowledge of
the pathophysiology of stroke. Understanding the benefits of timely reperfusion has led to …